Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma

• Published in: Journal of thrombosis and thrombolysis Vol. 55; no. 3; pp. 464 - 473
• Main Authors: Velasco-Rodríguez, Diego, Martínez-Alfonzo, Inés, Velasco-Valdazo, Alberto Eterio, Revilla, Nuria, Mahíllo-Fernández, Ignacio, Askari, Elham, Castro-Quismondo, Nerea, Laso, Rosa Vidal, Domingo-González, Amalia, Serrano-López, Juana, Prieto, Elena, Rosado, Belén, Blanchard, María Jesús, Martín-Herrero, Sara, García-Raso, Aránzazu, Bueno, María Ángeles, de la Plaza, Reyes, Peñaherrera, Meybi, López, Irene Gómez, López-Jiménez, Javier, Martínez-López, Joaquín, Llamas-Sillero, Pilar
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-04-2023; Springer Nature B.V
• Subjects: Anticoagulants - therapeutic use; Blood Coagulation Tests; Cardiology; Hematology; Heparin; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Medical records; Medicine; Medicine & Public Health; Molecular weight; Multiple myeloma; Multiple Myeloma - drug therapy; Patients; Phenotypes; Prophylaxis; Thrombin; Thrombophilia; Thrombophilia - diagnosis; Thrombophilia - drug therapy; Thrombophilia - etiology; Velocity; Venous Thromboembolism - drug therapy; Hypercoagulability; Thrombophilia; Thrombin generation; Thrombotic risk; Multiple myeloma
• ISSN: 1573-742X; 0929-5305; 1573-742X
• DOI: 10.1007/s11239-022-02765-8

The issue of how to identify newly diagnosed multiple myeloma (NDMM) patients requiring thromboprophylaxis remains unsolved. Several changes in thrombin generation (TG)-derived parameters have been described in multiple myeloma (MM) patients recently. Assessment of prothrombotic risk with a fully automated TG analyzer could reduce interlaboratory variability. Our objective was to determine whether ST-Genesia
®
could reveal a hypercoagulable state in NDMM compared to healthy controls. We conducted a multicenter observational study of NDMM requiring initial treatment to compare TG parameters obtained with ST-Genesia
®
analyzer and ST-ThromboScreen
®
reagent with a control group. Clinical data were obtained from medical records and blood samples were collected before initial anti-myeloma therapy. A thrombophilia panel was performed in all patients. Compared to age- and sex-matched controls (n = 83), NDMM patients (n = 83) had significantly higher peak height, higher velocity index, shorter time-to-peak and lower percentage of endogenous thrombin potential (ETP) inhibition after adding thrombomodulin (TM) (ETP%inh). NDMM on prophylactic low molecular weight heparin (LMWH) showed reduced both peak height and velocity index compared to NDMM who had not yet started VTE prophylaxis, similar to that of controls. Moreover, partial correction of ETP%inh was observed in MM patients on LMWH. The presence of a thrombophilia did not modify the TG phenotype. Untreated NDMM patients showed an enhanced TG, regardless of their thrombophilia status. They generate a higher peak of thrombin, take less time to produce it, and exhibit resistance to TM inhibition. Our findings suggest that standard prophylactic dose of LMWH may reduce TG at levels of healthy controls.